Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VBI Vaccines Inc.
< Previous
1
2
3
Next >
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
March 15, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union
February 25, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
February 23, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference
January 26, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio
January 05, 2022
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada
December 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
December 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in Jefferies London Healthcare Conference
November 16, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
November 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
October 13, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in Upcoming Investor Conferences
October 04, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
September 29, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 02, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Appoints Linda Bain to Board of Directors
July 07, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
July 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
June 29, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Present at Upcoming Scientific Conferences
June 17, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Results of Annual General Meeting
June 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
June 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
June 08, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in Upcoming Investor Conferences
June 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
May 21, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
May 20, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases
May 12, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 03, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
April 28, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
VBI Vaccines to Participate in National Securities Corporation’s Biotech Investor Summit
April 27, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Tickers
VBIV
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.